- PR Newswire•8 days ago
UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases
ATLANTA, March 15, 2017 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an insights-driven health and wellness program that is dedicated to promoting healthier lifestyles. Wellness 4U is a multi-channel health and wellness program that utilizes several initiatives aimed to elevate patient outcomes beyond therapeutic support for people living with immunologic disorders and their healthcare professionals. Key Wellness 4U programs include a Wellness 4U Activity Tracker, a health outcomes research collaboration with the IBD Support Foundation, a national wellness education panel speaker event series addressing the entire care team and a nurse practitioner/physician's assistant educational initiative.
- PR Newswire•17 days ago
First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk
BRUSSELS, March 6, 2017 /PRNewswire/ -- Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in human mature breast milk and to estimate the average daily infant dose of the drug in maternal breast milk, in accordance with guidance from the US Food & Drug Administration. The study used a bioanalytical assay specifically designed for CIMZIA, offering significantly improved sensitivity and specificity over previously used plasma assays. The reported results indicate minimal to no transfer of CIMZIA into breast milk, a minimal average daily infant dose, and a relative infant dose, considered to be in the acceptable range for breastfeeding.
- GlobeNewswire•19 days ago
New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Late-breaking, investigational 16- week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe ...
UCB.BR : Summary for UCB - Yahoo Finance
UCB S.A. (UCB.BR)
Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's Range||69.88 - 70.83|
|52 Week Range||54.84 - 74.72|
|PE Ratio (TTM)||20.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|